PI Pharma Insight

BNF presentation directory

Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.

Reset

Active filters

  • Product: Dasatinib
Presentation Product Chemical substance Chapter Items dispensed
Dasatinib 100mg tablets
0801050ANAAADAD
Dasatinib Dasatinib Malignant Disease and Immunosuppression No data available
Dasatinib 10mg/ml oral suspension
0801050ANAAAGAG
Dasatinib Dasatinib Malignant Disease and Immunosuppression No data available
Dasatinib 110.6mg tablets
0801050ANAAALAL
Dasatinib Dasatinib Malignant Disease and Immunosuppression No data available
Dasatinib 140mg tablets
0801050ANAAAEAE
Dasatinib Dasatinib Malignant Disease and Immunosuppression No data available
Dasatinib 15.8mg tablets
0801050ANAAAHAH
Dasatinib Dasatinib Malignant Disease and Immunosuppression No data available
Dasatinib 20mg tablets
0801050ANAAAAAA
Dasatinib Dasatinib Malignant Disease and Immunosuppression No data available
Dasatinib 39.5mg tablets
0801050ANAAAIAI
Dasatinib Dasatinib Malignant Disease and Immunosuppression No data available
Dasatinib 50mg tablets
0801050ANAAABAB
Dasatinib Dasatinib Malignant Disease and Immunosuppression No data available
Dasatinib 63.2mg tablets
0801050ANAAAJAJ
Dasatinib Dasatinib Malignant Disease and Immunosuppression No data available
Dasatinib 70mg tablets
0801050ANAAACAC
Dasatinib Dasatinib Malignant Disease and Immunosuppression No data available
Dasatinib 79mg tablets
0801050ANAAAKAK
Dasatinib Dasatinib Malignant Disease and Immunosuppression No data available
Dasatinib 80mg tablets
0801050ANAAAFAF
Dasatinib Dasatinib Malignant Disease and Immunosuppression No data available

Why monitor BNF codes?

Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.

Track cost pressure

Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.

Understand demand drivers

Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.